MetLife Investment Management’s Definium Therapeutics DFTX Stock Holding History

MetLife Investment Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.57M	Buy	75,859 +21,598	+40%	+$534K	0.02%	829
2026 Q1	$1.03M	Buy	54,261 +1,681	+3%	+$28.5K	0.01%	1381
2025 Q4	$704K	Buy	52,580 +3,384	+7%	+$41.9K	﹤0.01%	1623
2025 Q3	$580K	Hold	49,196	–	–	﹤0.01%	1734
2025 Q2	$319K	Hold	49,196	–	–	﹤0.01%	1919
2025 Q1	$288K	Sell	49,196 -466	-0.9%	-$3.34K	﹤0.01%	1996
2024 Q4	$346K	Buy	49,662 +7,113	+17%	+$48.9K	﹤0.01%	1995
2024 Q3	$242K	Buy	+42,549	New	+$296K	﹤0.01%	2189
2022 Q2	–	Sell	-9,745	Closed	-$162K	–	2890
2022 Q1	$162K	Buy	9,745 +524	+6%	+$9.09K	﹤0.01%	2476
2021 Q4	$191K	Buy	9,221 +3,070	+50%	+$98K	﹤0.01%	2076
2021 Q3	$215K	Sell	6,151 -2,244	-27%	-$97K	﹤0.01%	2051
2021 Q2	$434K	Buy	+8,395	New	+$441K	﹤0.01%	1651

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MetLife Investment Management's DFTX Position: Q2 2026 in Review

MetLife Investment Management increased its Definium Therapeutics (DFTX) stake by 40% in Q2 2026, buying an estimated $534K and bringing the position to 75,859 shares worth $3.57M. The position accounts for 0.02% of the portfolio, ranked #829.

MetLife Investment Management first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

MetLife Investment Management held 75,859 shares of Definium Therapeutics worth $3.57M as of Q2 2026.
MetLife Investment Management bought 21,598 Definium Therapeutics shares in Q2 2026, an estimated $534K.
Definium Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #829 holding.
MetLife Investment Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.